Identification

Name
Pheniramine
Accession Number
DB01620
Type
Small Molecule
Groups
Approved
Description

One of the histamine H1 antagonists with little sedative action. It is used in treatment of hay fever, rhinitis, allergic dermatoses, and pruritus. [PubChem]

Structure
Thumb
Synonyms
  • Feniramina
  • Pheniramine
  • Pheniraminum
Product Ingredients
IngredientUNIICASInChI Key
Pheniramine maleateNYW905655B132-20-7SSOXZAQUVINQSA-BTJKTKAUSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Allergy Eye DropsPheniramine maleate (3 mg/mL) + Naphazoline hydrochloride (.25 mg/mL)Solution / dropsOphthalmicCVS Health2013-01-25Not applicableUs
Allergy Eye DropsPheniramine maleate (0.315 %) + Naphazoline hydrochloride (0.02675 %)Solution / dropsOphthalmicBausch & Lomb Inc2013-02-27Not applicableCanada
Allergy Eye DropsPheniramine maleate (3 mg/mL) + Naphazoline hydrochloride (.25 mg/mL)Solution / dropsOphthalmicChain Drug Consortium2014-01-10Not applicableUs
Antitussive Decong Antihistamine SyrPheniramine maleate (6.5 mg) + Dextromethorphan hydrobromide (15 mg) + Mepyramine maleate (6.5 mg) + Phenylpropanolamine hydrochloride (13 mg)SyrupOralProdemdis Enr.1992-12-312001-04-26Canada
Bronchodex D CapPheniramine maleate (12.5 mg) + Chlorpheniramine maleate (1 mg) + Phenylpropanolamine hydrochloride (50 mg)Capsule, extended releaseOralProdemdis Enr.1981-12-312001-04-26Canada
Bronchodex PediatriquePheniramine maleate (5 mg) + Dextromethorphan hydrobromide (5 mg) + Guaifenesin (50 mg) + Pseudoephedrine hydrochloride (15 mg)SyrupOralTherapex Division De E Z Em Canada Inc1983-12-311997-07-22Canada
Bronchosirum Pour EnfantsPheniramine maleate (6.25 mg) + Dextromethorphan hydrobromide (15 mg) + Mepyramine maleate (6.25 mg) + Phenylpropanolamine hydrochloride (12.5 mg)SyrupOralBronchosirum Inc.1987-12-311997-08-05Canada
Caldomine Dh AdultePheniramine maleate (12.5 mg) + Hydrocodone bitartrate (5 mg) + Mepyramine maleate (12.5 mg) + Phenylpropanolamine hydrochloride (25 mg)LiquidOralTechnilab Pharma Inc.1981-12-312001-04-04Canada
Caldomine Dh EnfantPheniramine maleate (6.25 mg) + Hydrocodone bitartrate (1.667 mg) + Mepyramine maleate (6.25 mg) + Phenylpropanolamine hydrochloride (12.5 mg)LiquidOralTechnilab Pharma Inc.1982-12-312001-04-04Canada
Calmylin AcePheniramine maleate (7.5 mg) + Codeine phosphate (10 mg) + Guaifenesin (100 mg)SyrupOralTeva1996-12-31Not applicableCanada
International/Other Brands
AVIL
Categories
UNII
134FM9ZZ6M
CAS number
86-21-5
Weight
Average: 240.3434
Monoisotopic: 240.16264865
Chemical Formula
C16H20N2
InChI Key
IJHNSHDBIRRJRN-UHFFFAOYSA-N
InChI
InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3
IUPAC Name
dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine
SMILES
CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1

Pharmacology

Indication

Pheniramine is an antihistamine used to treat allergic conditions such as hay fever or urticaria.

Associated Conditions
Pharmacodynamics

Pheniramine is an antihistamine used to treat allergic conditions such as hay fever or urticaria. It is generally sold in combination with other medications, rather than as a stand-alone drug. Allergies are caused by an excessive type 1 hypersensitivity response of the body to allergens, mediated by inappropriate histamine signalling. By inhibiting the binding of histamine, antihistamines decrease the normal histamine response from cells, consequently decreasing allergic symptoms.

Mechanism of action

Antihistamines such as pheniramine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. Antihistamines suppress the histamine-induced wheal (swelling) and flare (vasodilation) response by blocking the binding of histamine to its receptors on nerves, vascular smooth muscle, glandular cells, endothelium, and mast cells. They effectively exert competitive antagonism of histamine for H1-receptors.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UNuclear receptor subfamily 1 group I member 3Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic hydroxylation, demethylation and glucuronidation.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Pheniramine H1-Antihistamine ActionDrug action
Pheniramine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Pheniramine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Pheniramine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Pheniramine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Pheniramine.Experimental, Illicit
AbexinostatThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Abexinostat.Investigational
AceprometazineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Aceprometazine.Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Pheniramine.Approved
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Pheniramine.Approved
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Pheniramine.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Pheniramine.Approved, Vet Approved
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Pheniramine.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Amifampridine.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Amitriptyline.Approved
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Pheniramine.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Pheniramine.Approved
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Pheniramine.Approved, Illicit, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Anagrelide.Approved
AntazolineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Antazoline.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Pheniramine.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Pheniramine.Approved, Investigational
AripiprazoleThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pheniramine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Pheniramine.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Pheniramine.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Pheniramine.Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Pheniramine.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Azelastine is combined with Pheniramine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Azithromycin.Approved
BedaquilineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Bedaquiline.Approved
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Pheniramine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Pheniramine.Approved, Illicit
Benzylpenicilloyl PolylysinePheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Besifloxacin.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Pheniramine.Approved, Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Pheniramine.Approved, Investigational
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pheniramine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Brompheniramine.Approved
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Pheniramine.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Pheniramine.Approved, Investigational
ButriptylineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Butriptyline.Approved
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Carbinoxamine.Approved
CeritinibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Pheniramine.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Pheniramine.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Pheniramine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Pheniramine.Approved, Investigational, Withdrawn
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Pheniramine.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Clemastine.Approved, Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClozapineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Clozapine.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Cocaine.Approved, Illicit
CrizotinibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Pheniramine is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Pheniramine.Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Pheniramine.Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Pheniramine.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Pheniramine.Approved, Investigational
DasatinibThe risk or severity of QTc prolongation can be increased when Dasatinib is combined with Pheniramine.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Pheniramine.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Delamanid.Approved, Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Pheniramine.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Pheniramine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Desloratadine.Approved, Investigational
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pheniramine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dexchlorpheniramine maleate.Approved
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Pheniramine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Pheniramine.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Pheniramine.Vet Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pheniramine.Approved, Investigational
DisopyramideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Disopyramide.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dolasetron.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Donepezil is combined with Pheniramine.Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Pheniramine.Approved
DoxepinThe risk or severity of QTc prolongation can be increased when Doxepin is combined with Pheniramine.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Pheniramine.Approved, Vet Approved
DronedaroneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dronedarone.Approved
DroperidolThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Droperidol.Approved, Vet Approved
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Pheniramine.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Eliglustat.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Emedastine.Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Pheniramine.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Entinostat.Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Pheniramine.Approved, Investigational
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Pheniramine.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Escitalopram.Approved, Investigational
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Pheniramine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pheniramine.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Pheniramine.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Pheniramine.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Pheniramine.Approved
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Pheniramine.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Pheniramine.Withdrawn
FluoxetineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Flupentixol.Approved, Investigational, Withdrawn
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Pheniramine.Approved, Investigational
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Pheniramine.Approved
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Pheniramine.Approved
GarenoxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Pheniramine.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Gemifloxacin.Approved, Investigational
GepefrineGepefrine may decrease the sedative and stimulatory activities of Pheniramine.Experimental
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Pheniramine.Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Goserelin.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Grepafloxacin.Approved, Investigational, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Haloperidol.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Pheniramine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pheniramine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Pheniramine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Pheniramine.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Pheniramine.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pheniramine.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ibutilide.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Iloperidone.Approved
ImatinibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Imatinib.Approved
ImipramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Imipramine.Approved
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Pheniramine.Approved
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Pheniramine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Pheniramine.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Pheniramine.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Pheniramine.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Pheniramine.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ivosidenib.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Pheniramine.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Pheniramine.Approved
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Pheniramine.Approved, Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Leuprolide.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Pheniramine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Pheniramine.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Levomethadyl Acetate.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Pheniramine.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lithium cation.Experimental
LomefloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lomefloxacin.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Loratadine.Approved, Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lumefantrine.Approved
MacimorelinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Macimorelin.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Pheniramine.Approved, Investigational
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Pheniramine.Approved, Investigational
MephedroneMephedrone may decrease the sedative and stimulatory activities of Pheniramine.Investigational
MephentermineMephentermine may decrease the sedative and stimulatory activities of Pheniramine.Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Pheniramine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Mequitazine is combined with Pheniramine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Mesoridazine.Approved, Investigational
MethadoneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Methadone.Approved
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Pheniramine.Approved, Illicit
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Pheniramine.Approved, Investigational
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Pheniramine.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pheniramine.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Pheniramine.Approved
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Pheniramine.Experimental, Illicit, Investigational
MifepristoneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Mifepristone.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Pheniramine.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Pheniramine.Approved
MMDAMMDA may decrease the sedative and stimulatory activities of Pheniramine.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Mocetinostat.Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Pheniramine.Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Moxifloxacin.Approved, Investigational
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Nalidixic Acid.Approved, Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Pheniramine.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Nemonoxacin.Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Pheniramine.Approved, Investigational
NilotinibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Nilotinib.Approved, Investigational
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Pheniramine.Approved
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Pheniramine.Approved
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Pheniramine.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Pheniramine.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Pheniramine.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Pheniramine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ondansetron.Approved
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Pheniramine.Vet Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Pheniramine.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Oxaliplatin.Approved, Investigational
OxatomideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Oxatomide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Pheniramine.Experimental
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pheniramine.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Paliperidone.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Papaverine.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Pheniramine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Pheniramine.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Pheniramine.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Pheniramine.Approved
PentamidineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pentamidine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Perflutren.Approved
PhenterminePhentermine may decrease the sedative and stimulatory activities of Pheniramine.Approved, Illicit
PimozideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pimozide.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Pheniramine.Experimental
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Pheniramine.Experimental
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Pheniramine.Approved, Investigational
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Pheniramine.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Pracinostat.Investigational
PrimaquineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Primaquine.Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Procainamide.Approved
PromazineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Pheniramine.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Propafenone.Approved
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Pheniramine.Approved, Investigational, Vet Approved
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Pheniramine.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Pheniramine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Pheniramine.Approved
QuetiapineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Quetiapine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Quinine.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Pheniramine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ricolinostat.Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Pheniramine.Approved
RisperidoneThe risk or severity of QTc prolongation can be increased when Risperidone is combined with Pheniramine.Approved, Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Pheniramine.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Pheniramine.Approved, Investigational
RomidepsinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Romidepsin.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Pheniramine.Approved, Investigational
RoxithromycinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Roxithromycin.Approved, Investigational, Withdrawn
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Pheniramine.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Rupatadine.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pheniramine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pheniramine.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Pheniramine.Vet Approved, Withdrawn
SertralineThe risk or severity of QTc prolongation can be increased when Sertraline is combined with Pheniramine.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Pheniramine.Approved, Vet Approved
SitafloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sitafloxacin.Experimental, Investigational
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Pheniramine.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Pheniramine.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sparfloxacin.Approved, Investigational
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Pheniramine.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sultopride.Experimental
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Pheniramine.Approved, Investigational
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Pheniramine.Approved
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Pheniramine.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Technetium Tc-99m ciprofloxacin.Investigational
TelavancinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Temafloxacin.Withdrawn
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Pheniramine.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Tetrabenazine.Approved, Investigational
ThioridazineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Pheniramine.Approved
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Pheniramine.Approved, Investigational
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Pheniramine.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Toremifene.Approved, Investigational
TrazodoneThe risk or severity of QTc prolongation can be increased when Trazodone is combined with Pheniramine.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Pheniramine.Approved, Investigational
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Pheniramine.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Trimipramine is combined with Pheniramine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Triprolidine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pheniramine.Approved, Vet Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TucidinostatThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Tucidinostat.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Pheniramine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Pheniramine.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Pheniramine.Approved
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Pheniramine.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Pheniramine.Approved, Investigational
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ziprasidone.Approved
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015557
PubChem Compound
4761
PubChem Substance
46505932
ChemSpider
4597
BindingDB
50017656
ChEBI
91591
ChEMBL
CHEMBL1193
Therapeutic Targets Database
DAP001063
PharmGKB
PA164744506
Wikipedia
Pheniramine
ATC Codes
R06AB05 — PheniramineD04AA16 — Pheniramine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidOral
Capsule, extended releaseOral
SprayNasal
Kit; powderOral
PowderOral
Kit; powder, for solutionOral
SolutionOphthalmic
Solution / dropsOphthalmic
SyrupOral
Powder, for solutionOral
Tablet, extended releaseOral
SuspensionOral
TabletOral
Powder, for suspensionOral
Granule, for solutionOral
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)181 °C at 1.30E+01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.377 mg/mLALOGPS
logP2.85ALOGPS
logP2.98ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)9.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity76.05 m3·mol-1ChemAxon
Polarizability28.41 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9719
Blood Brain Barrier+0.9657
Caco-2 permeable+0.9034
P-glycoprotein substrateSubstrate0.6248
P-glycoprotein inhibitor INon-inhibitor0.9048
P-glycoprotein inhibitor IINon-inhibitor0.966
Renal organic cation transporterInhibitor0.7942
CYP450 2C9 substrateNon-substrate0.7957
CYP450 2D6 substrateSubstrate0.7888
CYP450 3A4 substrateSubstrate0.5421
CYP450 1A2 substrateNon-inhibitor0.9442
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.5302
CYP450 2C19 inhibitorNon-inhibitor0.7433
CYP450 3A4 inhibitorNon-inhibitor0.9034
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9161
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9375
BiodegradationNot ready biodegradable0.9876
Rat acute toxicity2.9748 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9031
hERG inhibition (predictor II)Non-inhibitor0.516
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0920000000-fd728bb396d025cac3f0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-7af6ac1b513c7f2f33a9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-ea7e67a76460b33d8306
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-f5daabe4b8aedf8605e6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014j-0900000000-4ccd8055b59ae6eabc90
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-1900000000-deb31ec7e47ca6a0e3ff
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-1900000000-add8b8849c3db116e181
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-2900000000-c38a45f14fb4ab5b1687
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014r-3900000000-1f2c04e07e8c46a0c722
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0910000000-549410c48d9c44650beb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-669fdf1a00514df13bf2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-59e6f9e272a364ed620a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-a9b1b534a7a36bdaf014
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-0d3c0ba161b03c4cc7d5

Taxonomy

Description
This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pheniramines
Direct Parent
Pheniramines
Alternative Parents
Aralkylamines / Benzene and substituted derivatives / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Pheniramine / Aralkylamine / Benzenoid / Monocyclic benzene moiety / Heteroaromatic compound / Tertiary aliphatic amine / Tertiary amine / Azacycle / Organic nitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Leurs R, Bast A, Timmerman H: High affinity, saturable [3H]mepyramine binding sites on rat liver plasma membrane do not represent histamine H1-receptors. A warning. Biochem Pharmacol. 1989 Jul 1;38(13):2175-80. [PubMed:2567596]
  3. Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410]
  4. Nath C, Gupta MB: Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82. [PubMed:11526976]
  5. Karadag CH, Ulugol A, Dokmeci D, Dokmeci I: The role of histamine H1-receptors in the anticonvulsive effect of morphine against maximal electroconvulsive shock in mice. Jpn J Pharmacol. 1996 Jun;71(2):109-12. [PubMed:8835636]
  6. Nosal R, Drabikova K, Jancinova V, Moravcova J, Lojek A, Ciz M, Macickova T, Pecivova J: H1-antihistamines and oxidative burst of professional phagocytes. Neuro Endocrinol Lett. 2009;30 Suppl 1:133-6. [PubMed:20027159]
  7. Gepdiremen A, Buyukokuroglu ME, Hacimuftuoglu A, Suleyman H: Contribution of the histaminergic receptor subtypes to histamine-induced cerebellar granular neurotoxicity. Pol J Pharmacol. 2003 May-Jun;55(3):383-8. [PubMed:14506317]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Curator comments
Agonist at the canonical form of the receptor. Likely an antagonist at isoform 3 of the receptor.
General Function
Zinc ion binding
Specific Function
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name
NR1I3
Uniprot ID
Q14994
Uniprot Name
Nuclear receptor subfamily 1 group I member 3
Molecular Weight
39942.145 Da
References
  1. Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]

Drug created on August 29, 2007 14:15 / Updated on August 02, 2018 07:54